Hirokazu Kanegane
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Introduction Epstein–Barr virus‐associated hemophagocytic lymphohistiocytosis (EBV‐HLH) is highly prevalent in Asia. This study evaluated the safety and efficacy of a risk‐stratified treatment guided by dexamethasone (DEX) response and plasma EBV‐DNA levels. Our goal was to optimize etoposide dosing and establish a safer EBV‐HLH treatment. Methods We conducted a single‐arm, multicenter, risk‐stratified Phase II clinical trial, EBV‐HLH15, for EBV‐HLH. Patients were classified into three groups based on age, DEX response, and plasma EBV‐DNA load. In the low‐risk (LR) group, etoposide was eliminated from the treatment regimen. In the intermediate‐risk and high‐risk group (IR/HR group), etoposide dosing was reduced by up to 60% compared with the HLH‐2004 study to attenuate treatment intensity, whereas rituximab was added in the HR group to maintain it. Results Of 56 patients suspected of EBV‐HLH enrolled, 26 (14 in LR, eight in IR, and four in HR group) were eligible for EBV‐HLH15. The median age was 3.5 years (range: 1.0–8.0). The 1‐year overall survival of the LR and IR/HR groups was 100% and 81.5% (95% confidence interval [CI] = 43.5–95.1), respectively. The event‐free survival of the LR and IR/HR groups was 78.6% (95% CI = 47.2–92.5) and 58.3% (95% CI = 27.0–80.1), respectively. Most events (9/10, mainly deterioration or recurrence of HLH) occurred within 3 weeks of treatment initiation. No patients received rituximab as scheduled in Weeks 5 and 6. Conclusion Risk‐stratified treatment for EBV‐HLH guided by DEX response and plasma EBV‐DNA levels after 2 weeks of treatment was safe and effective.
Year:
2025
Discovered >70 years ago by Ogden Bruton, X-linked agammaglobulinemia (XLA), characterized by recurrent bacterial infections, hypo/agammaglobulinemia, and peripheral blood B-cell deficiency, is among the best-established inborn errors of immunity (IEIs) and one of the most well-documented single types of IEIs, the incidence of which is estimated to be between 1:100,000 and 1:200,000. However, although the pathogenesis of XLA is well understood, several issues remain open for discussion. In this review, we describe several unresolved issues, including noncoding BTK variants, contiguous deletion syndrome, Helicobacter infection, noninfectious neurodegeneration, renal involvement, and malignancies. The primary treatment for XLA, immunoglobulin replacement therapy, administered either intravenously or subcutaneously, has remained unchanged since its discovery. Allogeneic hematopoietic cell transplantation has been successful in some XLA patients, but there are still few reports. However, it may be considered as a treatment option in the future. Given that XLA is one of the most common types of IEIs, resolving these issues is a priority.
Year:
2025
Background Primary ciliary dyskinesia (PCD) is a rare genetic disease caused by defects in various genes affecting ciliary function. It is currently unclear why DRC1 gene variants are a relatively frequent cause of disease in Japanese and Korean patients. Methods A 12‐year‐old Japanese girl with bronchiectasis was suspected of PCD and examined using whole‐exome sequencing (WES). The breakpoint region was confirmed by Sanger sequencing and evaluation of transposable elements. Results Whole‐exome sequencing revealed a deletion of DRC1 exons 1–4 in the patient, followed by validation with Sanger sequencing. A DRC1 exon 1–4 deletion is recurrently observed in Japanese and Korean patients with PCD. All reported patients carry the same breakpoint region, which shows signs of Alu ‐mediated recombination. Intriguingly, common haplotypes were observed around the DRC1 gene in Japanese and Korean patients. Conclusion The recurrent DRC1 exon 1–4 deletion is therefore likely to be a founder variant and should be considered a major genetic cause of PCD in Japanese and Korean patients with PCD.
Year:
2024
Summary Germline gain-of-function (GOF) variants in the signal transducer and activator of transcription 3 (STAT3) gene is an inborn error of immunity presenting with autoimmunity and lymphoproliferation. Symptoms can vary widely, and no effective treatment has been established. This study investigated the efficacy of Janus kinase (JAK) inhibitors (JAKi) in patients with STAT3-GOF. Four patients were enrolled and their clinical symptoms before and after the initiation of treatment with JAKi were described. A cell stimulation assay was performed using Epstein-Barr virus transformed lymphoid cell lines (EBV-LCLs) that were derived from the patients with STAT3-GOF. The patients presented with various symptoms, and these symptoms mostly improved after the initiation of JAKi treatment. Upon interleukin-6 stimulation, the EBV-LCLs of patients showed enhanced STAT3 phosphorylation compared with those of the EBV-LCLs of healthy controls. In conclusion, four Japanese patients with STAT3-GOF were successfully treated with JAKi. JAKi ameliorated various symptoms and therefore, the use of JAKi could be an effective treatment option for patients with STAT3-GOF.
Year:
2023
Collaborators (1)
Yozo Nakazawa
-
Make your next move.
Prepare your application
Review drafts before you send them.